Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.003
Neutral
RSI(14)
38.536
Neutral
STOCH(KDJ)(9,3,3)
20.538
Neutral
ATR(14)
0.059
Low Volatility
CCI(14)
-109.763
Sell
Williams %R
87.500
Oversold
TRIX(12,20)
-0.923
Sell
StochRSI(14)
28.778
Sell
Search
Redhill Biopharma Ltd
RDHLAdd to Watchlist
0.635USD
+0.005+0.76%
Close 07-31 16:00（ET）Quotes delayed by 15 min
3.24MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+0.76%
5 Days
+0.35%
1 Month
-24.79%
6 Months
-47.91%
Year to Date
-38.30%
1 Year
-51.49%
Key Figures
0.687Open
0.687High
12.37KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
0.24%Turnover Ratio
0.631Prev. Close
0.653Low
7.71KTurnover
LossP/E Static
0.76P/B
0.00%Div Yield TTM
-37.25%ROA
3.31052wk High
0.19Volume Ratio
-8.27MNet Profit
5.09MShares
-0.1000EPS TTM
4.99Beta
-1708.61%ROE
0.71052wk Low
5.39%Amplitude
100.00%Gross Margin
3.24MMarket Cap
-4.35Reward/Risk
5.14%Risk Rate
TradingKey Stock Score of Redhill Biopharma Ltd
Currency: USD Updated: 2026-07-31Key Insights
Redhill Biopharma Ltd's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 125 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Redhill Biopharma Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Redhill Biopharma Ltd Highlights
StrengthsRisks
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
Growing
The company is in a growing phase, with the latest annual income totaling USD 286.00K.
Undervalued
The company’s latest PE is -6.50, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 504.44K shares, increasing 40.77% quarter-over-quarter.
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
Redhill Biopharma Ltd News
More news coming soon, stay tuned...
Indicators
Moving Average
Indicators
Value
Direction
MA5
0.679
Sell
MA10
0.677
Sell
MA20
0.701
Sell
MA50
0.826
Sell
MA100
0.864
Sell
MA200
1.028
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Redhill Biopharma Ltd Info
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
Ticker SymbolRDHL
CompanyRedhill Biopharma Ltd
CEOBen-Asher (Dror)
Websitehttps://www.redhillbio.com/
Shareholders
Related Instruments
-0.53%
+0.23%
-1.00%
-2.54%
+0.33%
-1.44%
-0.61%
-0.79%
-8.78%
+0.48%
+0.70%
-1.00%
-0.69%
+0.49%
-1.08%
+3.32%
0.00%
+1.34%
-0.87%
-2.17%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.640
-24.790 (-7.43%)
200.760
+5.720 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Redhill Biopharma Ltd (RDHL)?
The current price of Redhill Biopharma Ltd (RDHL) is 0.64.
What is the symbol of Redhill Biopharma Ltd?
The ticker symbol of Redhill Biopharma Ltd is RDHL.
What is the 52-week high of Redhill Biopharma Ltd?
The 52-week high of Redhill Biopharma Ltd is 3.31.
What is the 52-week low of Redhill Biopharma Ltd?
The 52-week low of Redhill Biopharma Ltd is 0.71.
What is the market capitalization of Redhill Biopharma Ltd?
The market capitalization of Redhill Biopharma Ltd is 3.24M.
What is the Earnings Per Share (EPS TTM) of Redhill Biopharma Ltd (RDHL)?
The Earnings Per Share (EPS TTM) of Redhill Biopharma Ltd (RDHL) is -0.10.